Are Peptides Legal in Georgia? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Georgia as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Georgia attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Georgia statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. Georgia does go further on at least one compound: Semaglutide, tirzepatide, liraglutide, sermorelin acetate, somatropin and hCG named as prescription-only dangerous drugs (details below). Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Georgia at a glance

State controlled-substances law: O.C.G.A. § 16-13-20 et seq. (Georgia Controlled Substances Act); Schedule III at § 16-13-27; Dangerous Drug Act at § 16-13-70 et seq. (codes.findlaw.com)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (O.C.G.A. § 16-13-27 (Schedule III); § 16-13-71 (dangerous drugs)) (codes.findlaw.com)
Research peptides scheduled by the state: Semaglutide, tirzepatide, liraglutide, sermorelin acetate, somatropin and hCG named as prescription-only dangerous drugs (O.C.G.A. § 16-13-71; possession without a prescription under § 16-13-72) (codes.findlaw.com)
Board of Pharmacy on compounded GLP-1s: No statement located
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. Georgia Composite Medical Board rule 360-3-.07 allows telemedicine where the licensee has examined the patient, acts at the request of a provider who has, or uses technology sufficient to equal an in-person exam; the licensee must make diligent efforts to have the patient seen in person at least annually, and the standard of care is the in-person standard. (law.cornell.edu)
State-level enforcement, 2023 to 2026: None found
Last verified: 28 September 2026, confidence high

The federal rules that apply in Georgia, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Georgia:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Georgia. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Georgia law adds

Georgia's controlled-substances law (O.C.G.A. § 16-13-20 et seq. (Georgia Controlled Substances Act); Schedule III at § 16-13-27; Dangerous Drug Act at § 16-13-70 et seq.) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

Compounds Georgia has scheduled or restricted

Semaglutide, tirzepatide, liraglutide, sermorelin acetate, somatropin and hCG named as prescription-only dangerous drugs (O.C.G.A. § 16-13-71; possession without a prescription under § 16-13-72) (codes.findlaw.com)

Human growth hormone

Human growth hormone is not in Georgia's Schedule III, which lists anabolic steroids only. Somatropin and chorionic gonadotropin are instead on the § 16-13-71 dangerous drug (prescription-only) list, alongside semaglutide, tirzepatide, liraglutide and sermorelin acetate. (O.C.G.A. § 16-13-27 (Schedule III); § 16-13-71 (dangerous drugs)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

No Georgia Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Georgia pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Georgia medical board guidance specific to peptide therapy was located. A Georgia prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Georgia

O.C.G.A. § 16-13-72 makes it unlawful to possess a dangerous drug without a prescription, and § 16-13-71 names semaglutide, tirzepatide, sermorelin, somatropin and hCG as dangerous drugs; unlisted research peptides such as BPC-157 fall outside both the schedules and the named list, so the federal rules apply to them. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into Georgia is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Georgia Composite Medical Board rule 360-3-.07 allows telemedicine where the licensee has examined the patient, acts at the request of a provider who has, or uses technology sufficient to equal an in-person exam; the licensee must make diligent efforts to have the patient seen in person at least annually, and the standard of care is the in-person standard. (law.cornell.edu) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Georgia law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Georgia

The Bureau found no Georgia-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. Georgia is unusual in naming the GLP-1 peptides and sermorelin in statute as prescription-only dangerous drugs, so holding those without a prescription is a misdemeanor under state law. No Georgia Board of Pharmacy, Composite Medical Board or attorney general statement on compounded GLP-1s or research peptides was found.

Frequently asked questions

Is BPC-157 legal in Georgia?

Georgia has not scheduled BPC-157, so possessing it is not a Georgia offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Georgia?

Yes. Georgia Composite Medical Board rule 360-3-.07 allows telemedicine where the licensee has examined the patient, acts at the request of a provider who has, or uses technology sufficient to equal an in-person exam; the licensee must make diligent efforts to have the patient seen in person at least annually, and the standard of care is the in-person standard. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Georgia?

Only with a valid prescription for an approved use. Georgia does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Georgia fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.